India Attracts MNC Drug Makers As Vaccine Market Growth Sector
This article was originally published in PharmAsia News
India is fast becoming attractive to multinational pharmaceutical companies as a place to market vaccines, once relegated to the back burner as among the less-profitable of product lines. GlaxoSmithKline, Novartis and Pfizer are looking at the market potential in India as they see vaccines as one of the more profitable segments of their drug lines. Vaccine sales in India are projected to grow at an annual rate of at least 16 percent, soon becoming a $1 billion market. Three-fifths of the vaccine market in India is pediatric. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.